CN108042505A - A kind of plant hollow capsule for being exclusively used in Cefixime - Google Patents
A kind of plant hollow capsule for being exclusively used in Cefixime Download PDFInfo
- Publication number
- CN108042505A CN108042505A CN201810000896.1A CN201810000896A CN108042505A CN 108042505 A CN108042505 A CN 108042505A CN 201810000896 A CN201810000896 A CN 201810000896A CN 108042505 A CN108042505 A CN 108042505A
- Authority
- CN
- China
- Prior art keywords
- cellulose
- capsule
- cefixime
- plant hollow
- hollow capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 163
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 title claims abstract description 55
- 229960002129 cefixime Drugs 0.000 title claims abstract description 55
- 238000004090 dissolution Methods 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 28
- 229920002678 cellulose Polymers 0.000 claims description 63
- 239000001913 cellulose Substances 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 20
- -1 hydroxypropoxy Chemical group 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000003292 glue Substances 0.000 claims description 10
- 229960003943 hypromellose Drugs 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000000704 physical effect Effects 0.000 abstract description 2
- 235000010980 cellulose Nutrition 0.000 description 52
- 241000196324 Embryophyta Species 0.000 description 43
- 238000004519 manufacturing process Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000007598 dipping method Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 238000007493 shaping process Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000206575 Chondrus crispus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 2
- 229950003779 propiram Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- TURGQPDWYFJEDY-UHFFFAOYSA-N 1-hydroperoxypropane Chemical compound CCCOO TURGQPDWYFJEDY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 244000275012 Sesbania cannabina Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical class OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UVKKGVAKIXSZMY-UHFFFAOYSA-N ethene;1h-pyrrole Chemical compound C=C.C=1C=CNC=1 UVKKGVAKIXSZMY-UHFFFAOYSA-N 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of plant hollow capsules for being exclusively used in Cefixime, have following performance：The Cefixime Capsules dissolution rate tested according to Chinese Pharmacopoeia method is more than 80%, higher than the capsule on current market, can improve the release absorption rate of Cefixime Capsules in vivo, quick.Meanwhile plant hollow capsule intensity of the invention and good toughness, friability is low, non-breakable during shipping storage, and physical property meets States Pharmacopoeia specifications and use demand.
Description
Technical field
The present invention relates to a kind of Capsuleses, and in particular to a kind of plant hollow capsule for being exclusively used in Cefixime.
Background technology
Cefixime is third generation oral cephalosporin, and bactericidal effect is played by inhibiting bacteria the synthesis of cell membrane.Head
Spore gram oxime is in vitro and in vivo to gram-positive cocci such as pneumococcus, micrococcus scarlatinae, and gram negative bacillus is such as
Bacillus influenzae, moraxelle catarrhalis, Escherichia coli, proteus mirabilis, gonococcus are respectively provided with good antibacterial action.Clinically cephalo
Gram oxime for caused by sensitive bacteria pharyngitis, tonsillitis, acute bronchitis, acute exacerbation of chronic bronchitis, tympanitis, urine
Road feel dye, Simple gonorrhea etc..
The cefixime preparation listed at present has capsule, tablet, dispersible tablet, chewable tablets, granule, dry suspensoid agent,
For oral administered dosage form.Cefixime preparation is all poor there are stability, and dissolution rate is relatively low, the absorption and distribution of drug in vivo
Relatively slowly, the problems such as affecting the treatment speed and effect of drug.
The technical indicator of Cefixime Capsules agent includes dissolution rate one.Dissolution rate characterization capsule is disintegrated molten in human body
The rate of change determines that drug in the in vivo rate of release of people, influences the soak time of drug and the therapeutic effect of drug in capsule.
Cefixime dissolution rate test method is that the capsule containing Cefixime is molten in specific dissolution medium under certain condition
Certain time is solved, tests the mass fraction for the Cefixime being dissolved.Dissolution medium as defined in Chinese Pharmacopoeia and Japanese Pharmacopoeia is not
Together.Wherein, dissolution medium as defined in Chinese Pharmacopoeia is the potassium dihydrogen phosphate buffer solution of pH=7.2.It is molten as defined in Japanese Pharmacopoeia
Go out disodium hydrogen phosphate-citric acid solution that medium is pH=7.5.
Cefixime Capsules agent is made of Capsules shell and its content Cefixime pharmaceutical composition, Capsules shell
Raw material and recipe-imposed Cefixime Capsules agent dissolution rate.Capsules shell is broadly divided into plant hollow capsule and gelatin is empty
Heart-soothing capsule, gelatin hollow capsule are formed by the collagenous portion degradation in the connective tissues such as animal skin, bone, sarolemma, flesh evil spirit
Gelatin is prepared, specific such as ox bone, pigskin；Plant hollow capsule is the Capsules using plant origin object as raw material, tool
Body includes hypromellose Capsules and Propiram Capsules etc..Hypromellose is the part first of cellulose
The poly- hydroxypropyl ether of base and part is a kind of non-ionic compound ether.Capsules prepared therefrom, compared with gelatine capsule, tool
There is the advantage that water content is low, chemical stability is good, toughness is high, moreover it can be used to which vegetarian, utilization are more extensive.
Inventor has found that Cefixime is in commercially available hypromellose Capsules, according to Chinese Pharmacopoeia method, day
Cefixime Capsules dissolution test method test described in this CP method, dissolution rate are below 80%, i.e., commercially available hydroxypropyl
Encapsulated methylcellulose is not suitable for Cefixime.It is therefore desirable to a kind of hypromellose glue suitable for Cefixime
Capsule.
The content of the invention
To solve the above-mentioned problems, Cefixime Capsules dissolution rate is improved, the present invention provides a kind of plant hollow capsule,
The Cefixime Capsules dissolution rate tested according to Chinese Pharmacopoeia method is more than 80%.
The inventors discovered that the plant hollow capsule including following components can reach the head tested according to Chinese Pharmacopoeia method
Spore gram oxime capsule dissolubility is more than 80% index：
The plant hollow capsule includes the first cellulose, second of cellulose and water, the first described fiber
For element at 20 DEG C, concentration is that the aqueous solution of 8wt% has the viscosity of 100~500mPas；Second of cellulose is 20
DEG C when, concentration be 8wt% aqueous solution have 10~99mPas viscosity；Water content is the 1~30% of Capsules weight.
Wherein, the cellulose be by glucose group into macromolecular polysaccharide and its derivative, specifically include natural fibre
Tie up one kind in element, methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hypromellose or their derivatives
It is or a variety of.
Further, the first described cellulose and second of cellulose are hypromellose or its derivative respectively
One or more in object.
Solution viscosity characterizes mobility and viscosity of the aqueous solution under certain temperature and pressure, during it is with aqueous solution
The relating to parameters such as the molecular weight of solute and concentration.The aqueous solution of the first cellulose has higher viscosity, containing such cellulose
Plant capsule has preferable intensity, and and is easy to be molded.The solution viscosity of second of cellulose is smaller, containing such cellulose
Plant capsule friability it is low, the dissolution rate of Cefixime Capsules is higher.Preferably, the first described cellulose is at 20 DEG C
When, concentration is that the aqueous solution of 8wt% has the viscosity of 200~400mPas；Second of cellulose is dense at 20 DEG C
The aqueous solution spent for 8wt% has the viscosity of 50~90mPas.
Further, the weight ratio of the first described cellulose and second of cellulose is 99/1~60/40.When first
When the weight ratio of kind cellulose and second of cellulose is more than 99/1, the brittleness of plant hollow capsule is high, and according to Chinese Pharmacopoeia
The dissolution rate of the Cefixime of method test is not up to standard；When the weight ratio of the first cellulose and second of cellulose is less than 60/40
When, the intensity of Capsules is poor, and also not up to standard according to the dissolution rate of the Cefixime Capsules of Chinese Pharmacopoeia method test.It is preferred that
The weight ratio of the first cellulose and second of cellulose is 90/10~80/20.
When water content does not meet the requirement of 1~30% (weight ratio) in plant hollow capsule, although capsule Cefixime
Remaining to for dissolution rate is up to standard, but mechanical performance, the performance of capsule can be impacted.It is aqueous when plant hollow capsule
Amount is less than 1% (weight ratio), and capsule is too crisp, easily damaged, influences the transport and storage of capsule；It is aqueous when plant hollow capsule
When amount is more than 30% (weight ratio), the barrier property of capsule is decreased obviously, and reduces the storage time and drug effect of the drug in capsule.It is excellent
Choosing, the water content of plant hollow capsule is 3~10% (weight ratios).
Further, the plant hollow capsule is big according to the Cefixime Capsules dissolution rate that Japanese Pharmacopoeia method is tested
In 80%.
Inventor has found that dissolution medium has large effect to the dissolution rate of Cefixime, and capsule is in Chinese Pharmacopoeia and Japan
Cefixime dissolution rate in the different dissolution mediums of States Pharmacopoeia specifications may be different.When the first cellulose and second
When the weight ratio of kind cellulose is 99/1~60/40, the Cefixime dissolution rate of capsule meets Chinese Pharmacopoeia regulation, but is not inconsistent day
This States Pharmacopoeia specifications.In order to meet regulation in Chinese Pharmacopoeia and Japanese Pharmacopoeia simultaneously, further, with the first cellulose and the
Two kinds of celluloses add up to 100 parts by weight meters, also containing the third 1~5 parts by weight of cellulose.The third described cellulose is 20
DEG C when, concentration be 8wt% aqueous solution have 501~1000mPas viscosity.The third cellulose, which helps to reduce, to be dissolved out
Capsule contributes to the Cefixime dissolution rate of Capsules to meet Chinese Pharmacopoeia simultaneously the sensibility of dissolution medium during degree test
With the regulation of Japanese Pharmacopoeia.Preferably, the third cellulose is at 20 DEG C, and the aqueous solution that concentration is 8wt% has 700~
The viscosity of 900mPas.Added up to by the first cellulose and second of cellulose in terms of 100 parts by weight, if the third cellulose
Content be less than 1 parts by weight, capsule is to the effect unobvious of the sensibility of dissolution medium during to reducing dissolution rate test；More than 5
Parts by weight can reduce the dissolution rate of Cefixime Capsules instead.Preferably 2~4 parts by weight.
Further, the hydroxypropoxy content of the first described cellulose and second of cellulose is 8~12% (quality
Percentage composition), the hydroxypropoxy content of the third cellulose is 4~7% (mass percentages).Inventor's discovery,
Meet these requirements the first, second and the third cellulose there is better characteristics, help to improve Capsules
The characteristics such as dissolution rate, friability, disintegration time limited.
Further, preferably, the plant hollow capsule of the present invention, is tested according to Chinese Pharmacopoeia method and Japanese Pharmacopoeia method
Cefixime Capsules dissolution rate be all higher than 90%.
Further, plant hollow capsule of the invention can also contain gelling agent, coagulant, plasticising as required
The additives such as agent, adhesive, PH conditioning agents, pigment, but preferable additives content is less than 5% (mass percent), it is further excellent
Choosing does not contain the additive beyond pigment.
Wherein, the gelling agent refers in capsule manufacturing process, can make hypromellose and its derivative water
Solution is gradually transformed into uniform semi-rigid solid gel and keeps former shaped additive.Can be acetylation gellan gum,
Deacetylation gellan gum, κ types carragheen, β types carragheen, ι types carragheen, agar, pectin, sodium alginate, xanthans, western Radix Astragali
In glue, Karaya Gum, locust bean gum, furcellaran, tamarind gum, tara gum, the poly- glue in sclerotium Portugal, microbial alginate or carbomer
One or more.
The coagulant refers in capsule manufacturing process, can improve hypromellose and its derivative aqueous solution
Gradually it is transformed into uniform semi-rigid solid gel and keeps the additive of original shape rate.Can be potassium chloride, chlorination
One or more in calcium, potassium phosphate or potassium citrate.
The plasticizer is the additive that can improve hypromellose and its derivative processing performance, Ke Yishi
Glycerine, D-sorbite, polyethylene glycol, ethylene glycol, ethyl acetate, 1,3 butylene glycol, 1,4 butanediols, xylitol, glycerine diethyl
One kind in ester, triacetin, monoacetin, mannitol, inositol, maltitol, glucose or polypropylene glycol etc.
It is or a variety of.
The adhesive can be starch, dextrin, polyethylene pyrrole network alkanone, carboxymethyl chitin, polyvinyl alcohol, sesbania
Glue, Arabic gum, meat silica gel, Propiram, elsinan, Indian gum, glucose or ethylene pyrrole network alkanone and vinyl acetate copolymerized
One or more in object.
The PH conditioning agents are used to adjust the pH value of the aqueous solution of raw material in plant hollow capsule preparation process, Ke Yishi
Sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium acid carbonate, saleratus, ammonium carbonate, sodium dihydrogen phosphate,
One or more in potassium dihydrogen phosphate or dipotassium hydrogen phosphate.
The pigment be can be plant hollow capsule colouring additive, can be turmeric, riboflavin, quinoline yellow,
One in chlorophyll, indigo, tomato red, capsanthin, lutein, anthocyanidin, beet red, titanium dioxide, calcium carbonate or arnotto etc.
Kind is a variety of.
Further, preferably, the plant hollow capsule of the present invention also has following performance：
Friability：Capsule is crushed in 50 and is no more than 5；
Disintegration time limited<10min；
Content of beary metal<40ppm.
Wherein, the mechanical strength of the friability reaction capsule of capsule ensures that plant hollow capsule and Cefixime Capsules exist
There is very low breakage rate in packaging and transportational process.
Disintegration refers to that all disintegration leaches or into particle solid pharmaceutical preparation under prescribed conditions, except insoluble coating material or broken
Outside broken capsule shells, it should all pass through sieve.Disintegration time limited refers to solid pharmaceutical preparation in defined medium, in defined manner into
Row checks that all disintegrations leach or the limit into particle and the time required to passing through sieve.In general, disintegration time limited is shorter, capsule
The therapeutic effect of agent is better.
Content of beary metal refers to the percentage composition of heavy metal in Capsules, and heavy metal is hazardous to the human body, and content is got over
It is low, it is smaller to the harm of human body.
More than performance can be measured according to the method that Chinese Pharmacopoeia is recorded.
Preferably, the plant hollow capsule has following performance：
Friability：Capsule is crushed in 50 and is no more than 2, is most preferably crushed without capsule；
Disintegration time limited<6min, most preferably<4min；
Content of beary metal<20ppm, most preferably<5ppm.
Further, the present invention also provides a kind of capsule, the capsule using the plant hollow capsule of the present invention as shell,
The content formed comprising one or more compositions in the derivative containing Cefixime or Cefixime.The present invention's
Capsule is suitable for treatment and infectious diseases, capsule caused by the bacterium of Cefixime sensitivity is entirely swallowed, in good taste, nothing
Peculiar smell, dissolution rate is high in vivo, there is better treatment rate and effect.
The effect of the present invention：
1st, the dissolution that the Cefixime Capsules loaded with the plant hollow capsule of the present invention are tested according to Chinese Pharmacopoeia method
Degree is more than 80%, higher than the capsule on current market, can improve the release absorption rate of Cefixime Capsules in vivo, see
Effect is fast.The Cefixime Capsules that the plant hollow capsule of optimization formula loads are tested according to Chinese Pharmacopoeia method and Japanese Pharmacopoeia method
Dissolution rate is both greater than 80%, and even greater than 90%, it can not only apply to Chinese market, Japanese market can also be applied to, have
There are good market prospects.
2nd, plant hollow capsule intensity of the invention and good toughness, friability is low, non-breakable during shipping storage,
Physical property meets States Pharmacopoeia specifications and use demand；Disintegration time limited is short, and drug easily discharges and absorbs, is quick in capsule；Plant is empty
The content of beary metal of heart-soothing capsule is low, low to the harm of human body.
It should be appreciated that such as " having ", "comprising" and " comprising " term used herein are not precluded from one or more
A other materials, ingredient, performance, state, element or the presence or addition of its combination；" being more than ", " being less than " all include numerical value sheet
Body.
Specific embodiment
It is further illustrated the present invention below by the mode of embodiment, does not therefore limit the present invention to the embodiment
Among scope.The techniques implemented on the basis of the foregoing are all within the scope of the present invention.For being familiar with this field
For personnel, other modification is easily achieved, thus it is general general being limited without departing substantially from claim and equivalency range
Under thought, the present invention is not limited to specific details.
Test event of the present invention and its assay method are as follows, unless otherwise instructed, each test all at 25 DEG C into
Row.
1st, Cefixime Capsules dissolution rate：
Chinese Pharmacopoeia test method：
By version in 2015《Chinese Pharmacopoeia》Cefixime Capsules dissolution test method is recorded to be tested.In Cefixime
Content in the tolerant Cefixime Capsules using the production of Shanghai marine rainbow company, content weight about 120mg/, active ingredient
Weight about 100mg/.During test, Shanghai marine rainbow is produced into the content in Cefixime Capsules and is loaded into test Capsules
In capsule (0#), loadings are 480 ± 5mg/, active ingredient about 400mg/.
Japanese Pharmacopoeia test method：
It presses《17th correction Pharmacopeia of Japan》The Cefixime Capsules dissolution test method of record is tested.Cephalo
Gram oxime content is using the content in Shanghai marine rainbow production Cefixime Capsules, content weight about 120mg/, active ingredient
Weight about 100mg/.During test, Shanghai marine rainbow is produced into the content in Cefixime Capsules and is loaded into test Capsules
In capsule (0#), loadings are 480 ± 5mg/, active ingredient about 400mg/.
2nd, friability：By version in 2015《Chinese Pharmacopoeia》The test method of four gelatin hollow capsule friabilities is surveyed
Examination.
3rd, disintegration time limited：By version in 2015《Chinese Pharmacopoeia》The test method of four gelatin hollow capsule disintegration time limiteds carries out
Test.
4th, content of beary metal：By version in 2015《Chinese Pharmacopoeia》The test method of four gelatin hollow capsule heavy metals carries out
Test.
5th, hydroxypropoxy content：By version in 2015《Chinese Pharmacopoeia》The assay of four hydroxypropyl methylcellulose propoxyls
Method is tested.
6th, viscosity：It is measured with dark type viscometer at 20 DEG C.
7th, water content：By version in 2015《Chinese Pharmacopoeia》Middle dry weightless mensuration is measured.
The raw material of plant hollow capsule prepared by the present invention：
The first cellulose
A1：The carefree production of South Korea, hydroxypropoxy content 8.3%, the viscosity for the aqueous solution that concentration is 8wt% is 113mPa
s；
A2：The carefree production of South Korea, hydroxypropoxy content 9.4%, the viscosity for the aqueous solution that concentration is 8wt% is 282mPa
s。
Second of cellulose
B1：The carefree production of South Korea, hydroxypropoxy content 9.4%, the viscosity for the aqueous solution that concentration is 8wt% is 42mPa
s；
B2：The carefree production of South Korea, hydroxypropoxy content 9.0%, the viscosity for the aqueous solution that concentration is 8wt% is 71mPa
s。
The third cellulose
C1：The carefree production of South Korea, hydroxypropoxy content 8.8%, the viscosity for the aqueous solution that concentration is 8wt% is 653mPa
s；
C2：The carefree production of South Korea, hydroxypropoxy content 6.2%, the viscosity for the aqueous solution that concentration is 8wt% is 875mPa
s。
Embodiment 1~13
According to the composition of raw materials shown in table 1, plant hollow capsule of the invention is prepared according to following preparation method：
1st, by the cellulose in table 1, (Examples 1 to 6 includes the first and second of cellulose, and embodiment 7~13 is also wrapped
Containing the third cellulose) and water mixing, the liquid that cellulose mass percentage is 25% is configured to, it is mixed to be heated to 90 DEG C of stirrings
It closes uniform；
2nd, mixed solution is cooled to 40~50 DEG C, stands 5h, be sent into capsule production line；
3rd, the preparation solution that will be fed into capsule production line is carried out with 0# molds after dipping in glue, shaping, is sent into drying baker, baking oven temperature
70 DEG C of degree dries certain time, after the water content for making Capsules is 10%, takes out cutting, body cap sleeve obtains plant sky after closing
Heart-soothing capsule finished product.Finished product is 0# Capsuleses, and weight is 98 ± 7mg/.
Table 1
Remarks："/" is represented without using the third cellulose.
Embodiment 14~18
According to the composition of raw materials shown in table 2, plant hollow capsule of the invention is prepared according to following preparation method.
1st, by table 1 cellulose (including the first, second and the third cellulose) and water mix, be configured to fiber
Plain mass percentage is 25% liquid, is heated to 90 DEG C and is uniformly mixed；
2nd, mixed solution is cooled to 40~50 DEG C, stands 5h, be sent into capsule production line；
3rd, the preparation solution that will be fed into capsule production line is carried out with 0# molds after dipping in glue, shaping, is sent into drying baker, baking oven temperature
70 DEG C of degree dries certain time, after making the water content of Capsules for the value shown in table 2, takes out cutting, body cap sleeve obtains after closing
Plant hollow capsule finished product.Finished product is 0# Capsuleses, and weight is 98 ± 7mg/.
Table 2
Comparative example 1
1st, the first cellulose A1 and water are mixed, is configured to the liquid that cellulose mass percentage is 25%, heating
It is uniformly mixed to 90 DEG C；
2nd, mixed solution is cooled to 40~50 DEG C, stands 5h, be sent into capsule production line；
3rd, the preparation solution that will be fed into capsule production line is carried out with 0# molds after dipping in glue, shaping, is sent into drying baker, baking oven temperature
70 DEG C of degree dries certain time, after the water content for making Capsules is 10%, takes out cutting, body cap sleeve obtains plant sky after closing
Heart-soothing capsule finished product.Finished product is 0# Capsuleses, and weight is 98 ± 7mg/.
Comparative example 2
1st, second of cellulose B1 and water are mixed, is configured to the liquid that cellulose percentage composition is 25%, is heated to 90
It DEG C is uniformly mixed；
2nd, mixed solution is cooled to 40~50 DEG C, stands 5h, be sent into capsule production line；
3rd, the preparation solution that will be fed into capsule production line is carried out with 0# molds after dipping in glue, shaping, is sent into drying baker, baking oven temperature
70 DEG C of degree dries certain time, after the water content for making Capsules is 10%, takes out cutting, body cap sleeve obtains plant sky after closing
Heart-soothing capsule finished product.Finished product is 0# Capsuleses, and weight is 98 ± 7mg/.
Comparative example 3
1st, the third cellulose C1 and water are mixed, is configured to the liquid that cellulose mass percentage is 25%, heating
It is uniformly mixed to 90 DEG C；
2nd, mixed solution is cooled to 40~50 DEG C, stands 5h, be sent into capsule production line；
3rd, the preparation solution that will be fed into capsule production line is carried out with 0# molds after dipping in glue, shaping, is sent into drying baker, baking oven temperature
70 DEG C of degree dries certain time, after the water content for making Capsules is 10%, takes out cutting, body cap sleeve obtains plant sky after closing
Heart-soothing capsule finished product.Finished product is 0# Capsuleses, and weight is 98 ± 7mg/.
With regard to the plant hollow capsule that embodiment and comparative example are prepared, corresponding performance survey is carried out to plant hollow capsule
Examination, test result are as shown in table 3 below.
Table 3
Capsule prepared by embodiment 1~18, friability crush capsule no more than 5 to test in 50, disintegration time limited<
10min, content of beary metal<5ppm.Wherein, the capsule that prepared by embodiment 10~13,17~18, friability do not have to test in 50
There is capsule to crush, disintegration time limited<4min, content of beary metal<5ppm.
Friability, disintegration time limited of plant hollow capsule etc. of the present invention has excellent performance, and content of beary metal is few, and from table
As can be seen that the Cefixime Capsules dissolution rate of these embodiments is both greater than according to the test of the test method of Chinese Pharmacopoeia in 3
80%.The Cefixime Capsules dissolution rate for implementing 7~18 is both greater than 80% according to Chinese Pharmacopoeia method and the test of Japanese Pharmacopoeia method, very
To more than 90%.In addition, the difference of plant hollow capsule water content (weight ratio), plant hollow capsule water content (weight ratio) is right
There are different in friability, dissolution rate and the disintegration time limited of capsule, and plant hollow capsule water content (weight ratio) is in preferred model
Friability, dissolution rate and the disintegration time limited of embodiment 13,17~18 in enclosing all are better than embodiment 14~16.
And the plant hollow capsule being prepared by comparative example, no matter Cefixime Capsules dissolution rate is according to Chinese Pharmacopoeia method
Or the test of Japanese Pharmacopoeia method, dissolution rate are both less than 80%, influence the rate of release and therapeutic effect of Cefixime.
Claims (10)
1. a kind of plant hollow capsule, which is characterized in that there is following performance：The Cefixime glue tested according to Chinese Pharmacopoeia method
Capsule dissolution rate is more than 80%.
2. plant hollow capsule according to claim 1, which is characterized in that the Cefixime tested according to Japanese Pharmacopoeia method
Capsule dissolubility is more than 80%.
3. plant hollow capsule according to claim 1, which is characterized in that surveyed according to Chinese Pharmacopoeia method and Japanese Pharmacopoeia method
The Cefixime Capsules dissolution rate of examination is all higher than 90%.
4. plant hollow capsule according to claim 1, which is characterized in that also with following performance：
Friability：Capsule is crushed in 50 and is no more than 5；
Disintegration time limited<10min；
Content of beary metal<40ppm.
5. plant hollow capsule according to claim 1, which is characterized in that including the first cellulose, second of fiber
Element and water, for the first described cellulose at 20 DEG C, the aqueous solution that concentration is 8wt% is viscous with 100~500mPas
Degree；For second of cellulose at 20 DEG C, concentration is that the aqueous solution of 8wt% has the viscosity of 10~99mPas；It is aqueous
It measures as the 1~30% of Capsules weight.
6. plant hollow capsule according to claim 5, which is characterized in that the first described cellulose and second of fibre
Dimension element is the one or more in hypromellose or derivatives thereof respectively.
7. plant hollow capsule according to claim 5, which is characterized in that the first described cellulose and second of fibre
The weight ratio of dimension element is 99/1~60/40, preferably 90/10~80/20.
8. plant hollow capsule according to claim 5, which is characterized in that with the first cellulose and second of cellulose
Total 100 parts by weight meters, also containing the third 1~5 parts by weight of cellulose, the third described cellulose is at 20 DEG C, concentration
There is the viscosity of 501~1000mPas for the aqueous solution of 8wt%.
9. plant hollow capsule according to claim 8, which is characterized in that the first described cellulose and second of fibre
The hydroxypropoxy content of dimension element is 8~12%, and the hydroxypropoxy content of the third cellulose is 4~7%.
10. a kind of capsule has used the plant hollow capsule described in claim 1~9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810000896.1A CN108042505A (en) | 2018-01-02 | 2018-01-02 | A kind of plant hollow capsule for being exclusively used in Cefixime |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810000896.1A CN108042505A (en) | 2018-01-02 | 2018-01-02 | A kind of plant hollow capsule for being exclusively used in Cefixime |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108042505A true CN108042505A (en) | 2018-05-18 |
Family
ID=62126151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810000896.1A Pending CN108042505A (en) | 2018-01-02 | 2018-01-02 | A kind of plant hollow capsule for being exclusively used in Cefixime |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108042505A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111388443A (en) * | 2020-05-14 | 2020-07-10 | 上海祺宇生物科技有限公司 | Cellulose empty capsule and capsule thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889987A (en) * | 2009-11-16 | 2010-11-24 | 江苏亚邦强生药业有限公司 | Method for preparing novel cefixime tablets and cefixime capsules |
| CN102119026A (en) * | 2008-06-13 | 2011-07-06 | 葛兰素集团有限公司 | Hydroxypropyl cellulose capsule shell |
| CN103110607A (en) * | 2013-03-01 | 2013-05-22 | 浙江华立南湖制药有限公司 | Cefixime capsule and preparation method thereof |
| CN105496984A (en) * | 2015-12-18 | 2016-04-20 | 石药集团欧意药业有限公司 | Cefixime capsule stable in quality and preparation method thereof |
| CN103536578B (en) * | 2013-11-05 | 2016-06-15 | 天津医药集团津康制药有限公司 | A kind of Cefixime Capsules and preparation method thereof |
| CN105997931A (en) * | 2016-07-19 | 2016-10-12 | 南京正宽医药科技有限公司 | Cefixime capsules and preparation method thereof |
-
2018
- 2018-01-02 CN CN201810000896.1A patent/CN108042505A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119026A (en) * | 2008-06-13 | 2011-07-06 | 葛兰素集团有限公司 | Hydroxypropyl cellulose capsule shell |
| CN101889987A (en) * | 2009-11-16 | 2010-11-24 | 江苏亚邦强生药业有限公司 | Method for preparing novel cefixime tablets and cefixime capsules |
| CN103110607A (en) * | 2013-03-01 | 2013-05-22 | 浙江华立南湖制药有限公司 | Cefixime capsule and preparation method thereof |
| CN103536578B (en) * | 2013-11-05 | 2016-06-15 | 天津医药集团津康制药有限公司 | A kind of Cefixime Capsules and preparation method thereof |
| CN105496984A (en) * | 2015-12-18 | 2016-04-20 | 石药集团欧意药业有限公司 | Cefixime capsule stable in quality and preparation method thereof |
| CN105997931A (en) * | 2016-07-19 | 2016-10-12 | 南京正宽医药科技有限公司 | Cefixime capsules and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111388443A (en) * | 2020-05-14 | 2020-07-10 | 上海祺宇生物科技有限公司 | Cellulose empty capsule and capsule thereof |
| CN111388443B (en) * | 2020-05-14 | 2021-12-31 | 上海祺宇生物科技有限公司 | Cellulose empty capsule and capsule thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1057862B1 (en) | Polymer film compositions for capsules | |
| EP1117736B2 (en) | Modified starch film compositions | |
| EP1045000B1 (en) | Cellulose ether films | |
| US20070254024A1 (en) | Process for manufacturing films | |
| US6635275B1 (en) | Modified starch film compositions | |
| EP1748763A1 (en) | Improved pullulan capsules | |
| JPWO2006082842A1 (en) | Hard capsule with improved solubility | |
| EP1580229A1 (en) | Biopolymer compositons and products thereof | |
| EP2600849A1 (en) | Film-forming composition for soft capsules | |
| EP1072633A1 (en) | Pullulan film compositions | |
| CN115429771B (en) | Composite glue for capsules and preparation method and application thereof | |
| CN107929258A (en) | A kind of plant hollow capsule | |
| CN108042505A (en) | A kind of plant hollow capsule for being exclusively used in Cefixime | |
| WO2021145296A1 (en) | Hard capsule containing cellulose derivative as base material and having improved mechanical strength and oxygen permeability | |
| CN110507629B (en) | Plant cellulose soft capsule rubber and preparation method thereof | |
| WO2022244713A1 (en) | Non-gelatin hard capsule and method for producing same | |
| CN116196289A (en) | Medical capsule composite adhesive and raw material proportion and preparation method thereof | |
| HK1024013B (en) | Polymer film compositions for capsules | |
| HK1186973A (en) | Film-forming composition for soft capsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180518 |
|
| WD01 | Invention patent application deemed withdrawn after publication |